Kiniksa Pharmaceuticals International (NASDAQ:KNSA) Posts Quarterly Earnings Results, Hits Estimates

Kiniksa Pharmaceuticals International (NASDAQ:KNSA) released its quarterly earnings results on Tuesday. The company reported $0.30 earnings per share (EPS) for the quarter, hitting the consensus estimate of $0.30, FiscalAI reports. Kiniksa Pharmaceuticals International had a return on equity of 14.16% and a net margin of 9.59%.The business had revenue of $243.60 million during the quarter, compared to the consensus estimate of $226.49 million.

Here are the key takeaways from Kiniksa Pharmaceuticals International’s conference call:

• ARCALYST revenue rose 55% year over year to $243.6 million in Q2 2026, an increase of more than $29 million sequentially. Management raised full-year revenue guidance to $980 million–$995 million from $930 million–$945 million.
• Commercial momentum strengthened, with approximately 450 new prescribers and 150 additional repeat prescribers added during the quarter. ARCALYST penetration in the multiple-recurrence population reached approximately 21%, leaving substantial room for expansion.
• Kiniksa advanced KPL-387 into the pivotal PASTEURAL Phase III trial in recurrent pericarditis, evaluating a 300 mg monthly dose after Phase II data showed rapid and sustained treatment response. The company anticipates a potential launch in 2028–2029.
• KPL-387’s Phase II data showed median treatment response in four days and CRP normalization in eight days, with tolerability consistent with IL-1 pathway inhibition; however, the disclosed analysis was interim and detailed follow-up information remained limited.
• Operating income was $27.2 million, net income was $25.4 million, and quarter-end cash was $525.9 million after approximately $58 million of net cash generation. Collaboration profit increased 68% year over year to $176.1 million despite continued investments in commercialization and clinical development.

Kiniksa Pharmaceuticals International Price Performance

NASDAQ:KNSA traded down $1.39 on Thursday, reaching $79.53. The stock had a trading volume of 76,445 shares, compared to its average volume of 728,682. The company has a market cap of $6.12 billion, a price-to-earnings ratio of 81.93 and a beta of 0.07. The firm’s fifty day moving average is $58.13 and its two-hundred day moving average is $50.71. Kiniksa Pharmaceuticals International has a 12-month low of $29.90 and a 12-month high of $82.94.

Wall Street Analysts Forecast Growth

Several research firms have weighed in on KNSA. Wall Street Zen downgraded shares of Kiniksa Pharmaceuticals International from a “strong-buy” rating to a “buy” rating in a report on Sunday, July 12th. JPMorgan Chase & Co. increased their price target on shares of Kiniksa Pharmaceuticals International from $72.00 to $107.00 and gave the company an “overweight” rating in a research report on Wednesday. Jefferies Financial Group raised their price objective on shares of Kiniksa Pharmaceuticals International from $58.00 to $71.00 and gave the stock a “buy” rating in a research note on Tuesday, April 28th. Canaccord Genuity Group lifted their price objective on Kiniksa Pharmaceuticals International from $64.00 to $98.00 and gave the stock a “buy” rating in a research report on Wednesday. Finally, Zacks Research raised Kiniksa Pharmaceuticals International from a “hold” rating to a “strong-buy” rating in a research note on Wednesday, June 17th. One analyst has rated the stock with a Strong Buy rating, eight have assigned a Buy rating and one has issued a Hold rating to the stock. According to MarketBeat.com, Kiniksa Pharmaceuticals International presently has a consensus rating of “Buy” and a consensus price target of $85.50.

Insider Transactions at Kiniksa Pharmaceuticals International

In related news, CEO Sanj K. Patel sold 48,565 shares of the firm’s stock in a transaction that occurred on Friday, May 1st. The shares were sold at an average price of $54.02, for a total transaction of $2,623,481.30. Following the sale, the chief executive officer owned 48,565 shares in the company, valued at approximately $2,623,481.30. This trade represents a 50.00% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider John F. Paolini sold 58,424 shares of Kiniksa Pharmaceuticals International stock in a transaction that occurred on Friday, May 1st. The stock was sold at an average price of $53.71, for a total transaction of $3,137,953.04. Following the completion of the sale, the insider directly owned 65,623 shares of the company’s stock, valued at $3,524,611.33. The trade was a 47.10% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders own 51.98% of the company’s stock.

Institutional Inflows and Outflows

A number of large investors have recently made changes to their positions in KNSA. Rubric Capital Management LP grew its position in shares of Kiniksa Pharmaceuticals International by 2.3% in the third quarter. Rubric Capital Management LP now owns 4,000,000 shares of the company’s stock valued at $155,320,000 after purchasing an additional 90,194 shares during the period. Arrowstreet Capital Limited Partnership boosted its stake in Kiniksa Pharmaceuticals International by 45.3% in the 3rd quarter. Arrowstreet Capital Limited Partnership now owns 1,068,263 shares of the company’s stock worth $41,481,000 after buying an additional 332,846 shares during the last quarter. Qube Research & Technologies Ltd boosted its stake in Kiniksa Pharmaceuticals International by 277.8% in the 2nd quarter. Qube Research & Technologies Ltd now owns 888,364 shares of the company’s stock worth $24,581,000 after buying an additional 653,236 shares during the last quarter. Millennium Management LLC grew its holdings in Kiniksa Pharmaceuticals International by 8.7% in the 1st quarter. Millennium Management LLC now owns 847,124 shares of the company’s stock valued at $18,815,000 after buying an additional 67,452 shares during the period. Finally, Goldman Sachs Group Inc. grew its holdings in Kiniksa Pharmaceuticals International by 51.8% in the 4th quarter. Goldman Sachs Group Inc. now owns 829,417 shares of the company’s stock valued at $34,213,000 after buying an additional 282,907 shares during the period. Hedge funds and other institutional investors own 53.95% of the company’s stock.

Key Stories Impacting Kiniksa Pharmaceuticals International

Here are the key news stories impacting Kiniksa Pharmaceuticals International this week:

• Positive Sentiment: Kiniksa reported second-quarter earnings of $0.30 per share, matching consensus estimates and rising from $0.23 a year earlier. Revenue reached $243.6 million, exceeding the $226.5 million analyst estimate. Kiniksa Pharmaceuticals International Q2 Earnings Match Estimates
• Positive Sentiment: The company raised its 2026 revenue guidance and highlighted advancement of its development pipeline, prompting a 29.6% share-price rally in the reported session. Higher expected revenue and pipeline progress improve the outlook for growth. Why Kiniksa Pharmaceuticals Is Up After Raising 2026 Revenue Guidance and Advancing Pipeline
• Positive Sentiment: Several analysts raised their price targets following the update: JPMorgan to $107 with an overweight rating, Canaccord Genuity to $98 with a buy rating, Wedbush to $99 with an outperform rating, and Citi to $100 with a buy rating. These revisions signal increased confidence in Kiniksa’s earnings and commercial outlook. Analyst Price Target Revisions
• Neutral Sentiment: Kiniksa scheduled its second-quarter 2026 financial-results announcement for July 28, providing the latest formal update on operating performance and guidance. Kiniksa Pharmaceuticals Announces Q2 2026 Financial Results
• Negative Sentiment: One valuation analysis contends that KNSA may be approximately 16% overvalued even after the raised 2026 guidance. With the stock trading near its 12-month high and at an elevated earnings multiple, valuation-related profit-taking remains a risk. Could Kiniksa Pharmaceuticals Be 16% Overvalued After Raised 2026 Guidance?

About Kiniksa Pharmaceuticals International

Kiniksa Pharmaceuticals International, Inc is a biopharmaceutical company focused on discovering, acquiring and developing therapeutics for patients suffering from lifethreatening and debilitating immune-mediated diseases. Founded in 2013 and headquartered in Lexington, Massachusetts, Kiniksa applies a patient-centric approach to build a diversified portfolio of marketed medicines and clinical-stage candidates targeting inflammation and immunology. The company’s core mission is to address complex conditions with significant unmet medical needs by advancing both novel and differentiated therapies.

The company’s lead marketed product is Ilaris (canakinumab), an interleukin-1β blocker licensed for the treatment of cryopyrin-associated periodic syndromes, systemic juvenile idiopathic arthritis, adult-onset Still’s disease and Schnitzler syndrome.